ArticleBMJ open2019
Diabetes and cardiovascular disease risk screening model in community pharmacies in a developing primary healthcare system: a feasibility study.
Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Pooled it
- HbA1c measurement using capillary blood in epidemiological studies: a scoping review of technologies and approaches.BMC endocrine disorders · 2026Article
- Examining public perceptions of cardiovascular disease risk screening programs in community pharmacies: a mixed-methods study.BMC public health · 2026Article
- Designing and implementing a prediabetes screening in community pharmacies and online prevention program: findings from the PREDICT study.BMC public health · 2026Article
- Article
- Diabetes risk assessment in Polish community pharmacies. Results from a pilot national screening campaign.Archives of medical science : AMS · 2026Article
- Health quality management practises for cardiovascular diseases, diabetes, and obesity care in the UAE: a scoping review.Frontiers in public health · 2025Article
- A stakeholders' perspective on enhancing community pharmacists' roles in controlling non-communicable diseases in the United Arab Emirates.Journal of pharmaceutical policy and practice · 2024Article
- Metabolic Syndrome in Adults Receiving Clozapine; The Need for Pharmacist Support.Pharmacy (Basel, Switzerland) · 2023Article
- Community pharmacists' perspectives on cardiovascular disease pharmaceutical care in the United Arab Emirates: a questionnaire survey-based analysis.Frontiers in pharmacology · 2023Article
- Diabetes and Cardiovascular Diseases Risk Assessment in Community Pharmacies: An Implementation Study.International journal of environmental research and public health · 2022Article
- Article
- Physicians' views on cardiovascular disease risk prevention services by pharmacists and potential for collaboration.Exploratory research in clinical and social pharmacy · 2021Article
- Article
- Implications Derived from Global Experiences of Barriers to Integrating Community Pharmacists into Primary Healthcare: A Scoping Review.Journal of primary care & community healthArticle
- Evaluation of patients' knowledge about their medications: A cross-sectional study in Qassim region, Saudi Arabia.The journal of medicine accessArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to develop an evidence-based community pharmacist-delivered screening model for diabetes and cardiovascular disease (CVD), and assess its feasibility to identify and refer patients with elevated risk.
designA feasibility study.
settingA purposive sample of 12 community pharmacies in three cities in the United Arab Emirates (UAE).
participantsAdults 40 years of age and above who have not been previously diagnosed with either diabetes or CVD.
interventionPharmacist screening of adults visiting pharmacies involved history, demographics, anthropometric measurements, blood pressure and point-of-care testing including glycated haemoglobin (HbA1c) levels and lipid panel. Participants with a 10-year CVD risk ≥7.5%, HbA1c level ≥5.7% or American Diabetes Association (ADA) risk score ≥5 points were advised to visit their physician. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcomes were (1) development of UAE pharmacist-delivered screening model, (2) the proportion of screened participants identified as having high CVD risk (atherosclerotic CVD 10-year risk defined as ≥7.5%) and (3) the proportion of participants identified as having elevated blood glucose (high HbA1c level ≥5.7% (38.8 mmol/mol)) or high self-reported diabetes risk (ADA risk score ≥5 points). Secondary outcome is participants' satisfaction with the screening.
resultsThe first UAE pharmacist-delivered screening model was developed and implemented. A total of 115 participants were screened, and 92.3% of the entire screening process was completed during a single visit to pharmacy. The mean duration of the complete screening process was 27 min. At-risk individuals (57.4%) were referred to their physicians for further testing, while 94.5% of participants were at least satisfied with their screening experience.
conclusionsThe community pharmacist-delivered screening of diabetes and CVD risk is feasible in the UAE. The model offers a platform to increase screening capacity within primary care and provides an opportunity for early detection and treatment. However, pathways for the integration of the pharmacist-delivered screening service with physicians in primary care are yet to be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.